CAM
NBIX icon

Capstone Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Capstone Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$215K Sell
4,666
-280
-6% -$13.6K 0.01% 1476
2017
Q1 		$214K Buy
+4,946
New +$212K 0.01% 1501

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Asset Management's NBIX Position: Q2 2017 in Review

Capstone Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 5.7% in Q2 2017, selling an estimated $13.6K and leaving 4,666 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #1476.

Capstone Asset Management first reported a position in NBIX in Q1 2017 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

  • Capstone Asset Management held 4,666 shares of Neurocrine Biosciences worth $215K as of Q2 2017.
  • Capstone Asset Management sold 280 Neurocrine Biosciences shares in Q2 2017, an estimated $13.6K.
  • Neurocrine Biosciences made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1476 holding.
  • Capstone Asset Management first reported a position in Neurocrine Biosciences in Q1 2017 and has held it in 2 quarters since.
  • 221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.